Key Takeaways
- • Vitroscope, a Trondheim, Norway-based company, raised $7M to scale its live-tissue platform, according to a Business Wire press release dated November 3, 2026.
- • The round comprises a $5M seed financing co-led by Cerberus Ventures and YZR Capital, plus $2M from the Research Council of Norway.
- • The company positions its platform within drug discovery, with the release tagged #DrugDiscovery.
Summary
Vitroscope has raised $7 million to scale its live-tissue platform, according to a Business Wire press release issued from Trondheim, Norway. The financing consists of a $5 million seed round co-led by Cerberus Ventures and YZR Capital, supplemented by $2 million from the Research Council of Norway, the country's public research funding body.
The release frames the funding as intended to scale the company's live-tissue platform and tags the announcement under drug discovery. The source material does not provide further detail on the platform's technical architecture, commercial stage, customer base, or valuation, and no additional perspectives were available to supplement those details.
The combination of venture capital and public research grant funding is a common structure for early-stage life sciences companies seeking to advance technology from research toward commercial application. Investors tracking drug discovery tools may look to subsequent disclosures for milestones, partnerships, or use of proceeds.
The release frames the funding as intended to scale the company's live-tissue platform and tags the announcement under drug discovery. The source material does not provide further detail on the platform's technical architecture, commercial stage, customer base, or valuation, and no additional perspectives were available to supplement those details.
The combination of venture capital and public research grant funding is a common structure for early-stage life sciences companies seeking to advance technology from research toward commercial application. Investors tracking drug discovery tools may look to subsequent disclosures for milestones, partnerships, or use of proceeds.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.